PE20240117A1 - Polipeptido especifico para mucina 1 y sus usos - Google Patents
Polipeptido especifico para mucina 1 y sus usosInfo
- Publication number
- PE20240117A1 PE20240117A1 PE2023001953A PE2023001953A PE20240117A1 PE 20240117 A1 PE20240117 A1 PE 20240117A1 PE 2023001953 A PE2023001953 A PE 2023001953A PE 2023001953 A PE2023001953 A PE 2023001953A PE 20240117 A1 PE20240117 A1 PE 20240117A1
- Authority
- PE
- Peru
- Prior art keywords
- polynucleotide
- vector
- seq
- polypeptide
- mucin
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 102000007298 Mucin-1 Human genes 0.000 title abstract 2
- 108010008707 Mucin-1 Proteins 0.000 title abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 5
- 108091033319 polynucleotide Proteins 0.000 abstract 5
- 239000002157 polynucleotide Substances 0.000 abstract 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 abstract 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000000735 allogeneic effect Effects 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000000139 costimulatory effect Effects 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464469—Tumor associated carbohydrates
- A61K39/46447—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/54—Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Refiere a un polipeptido que se une especificamente a mucina 1, el cual comprende una region variable de cadena pesada (VH) y una region variable de cadena ligera (VL), cada una con tres regiones determinantes de complementariedad (CDR) representadas por las secuencias SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, entre otras; unidas entre si mediante un ligador representado por la secuencia de aminoacidos GGGGSGGGGSGGGAS. Ademas, con respecto al presente polipeptido, se reivindica un polinucleotido aislado que lo codifica, un vector que comprende al polinucleotido y una celula que comprende al vector. Tambien, se reivindica un receptor de antigeno quimerico que incluye al presente polipeptido en un dominio extracelular, y que comprende un dominio transmembrana de CD28 o CD8, un dominio de senalizacion de CD3 zeta y dominios coestimuladores de CD28, OX-40 o 4-1BB (CD137). Ademas, con respecto a dicho receptor, se reivindica un polinucleotido aislado que lo codifica, un vector que porta el polinucleotido, y una celula inmunitaria T autologa o T alogenica que lo expresa. La presente a su vez refiere a una composicion que incluye principalmente al polinucleotido y un metodo para prevenir o tratar el cancer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200183768 | 2020-12-24 | ||
| KR20210137757 | 2021-10-15 | ||
| PCT/KR2021/019790 WO2022139537A2 (ko) | 2020-12-24 | 2021-12-24 | 뮤신 1에 특이적인 폴리펩티드 및 이의 이용 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240117A1 true PE20240117A1 (es) | 2024-01-22 |
Family
ID=82159981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001953A PE20240117A1 (es) | 2020-12-24 | 2021-12-24 | Polipeptido especifico para mucina 1 y sus usos |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4265640A2 (es) |
| JP (1) | JP2024503803A (es) |
| KR (1) | KR20220092432A (es) |
| AU (1) | AU2021410416A1 (es) |
| CA (1) | CA3203067A1 (es) |
| CL (1) | CL2023001873A1 (es) |
| CO (1) | CO2023009764A2 (es) |
| IL (1) | IL303902A (es) |
| MX (1) | MX2023007665A (es) |
| PE (1) | PE20240117A1 (es) |
| TW (1) | TW202233667A (es) |
| WO (1) | WO2022139537A2 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4976001A (en) * | 2000-03-30 | 2001-10-15 | Dyax Corp | Mucin-1 specific binding members and methods of use thereof |
| US10208125B2 (en) * | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| MY195529A (en) | 2016-11-18 | 2023-01-30 | Astellas Pharma Inc | Novel Anti-Human MUC1 Antibody Fab Fragment |
| CN111201240B (zh) * | 2017-03-21 | 2024-03-22 | 株式会社菲特伦 | 特异性地结合muc1的抗体及其用途 |
| WO2018174544A2 (ko) | 2017-03-21 | 2018-09-27 | 주식회사 펩트론 | Muc1에 특이적으로 결합하는 항체 및 그의 용도 |
-
2021
- 2021-12-23 KR KR1020210186471A patent/KR20220092432A/ko unknown
- 2021-12-24 MX MX2023007665A patent/MX2023007665A/es unknown
- 2021-12-24 WO PCT/KR2021/019790 patent/WO2022139537A2/ko active Application Filing
- 2021-12-24 JP JP2023539197A patent/JP2024503803A/ja active Pending
- 2021-12-24 PE PE2023001953A patent/PE20240117A1/es unknown
- 2021-12-24 EP EP21911602.7A patent/EP4265640A2/en active Pending
- 2021-12-24 CA CA3203067A patent/CA3203067A1/en active Pending
- 2021-12-24 TW TW110148778A patent/TW202233667A/zh unknown
- 2021-12-24 AU AU2021410416A patent/AU2021410416A1/en active Pending
- 2021-12-24 IL IL303902A patent/IL303902A/en unknown
-
2023
- 2023-06-22 CL CL2023001873A patent/CL2023001873A1/es unknown
- 2023-07-24 CO CONC2023/0009764A patent/CO2023009764A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4265640A2 (en) | 2023-10-25 |
| KR20220092432A (ko) | 2022-07-01 |
| MX2023007665A (es) | 2023-07-07 |
| JP2024503803A (ja) | 2024-01-29 |
| AU2021410416A1 (en) | 2023-08-10 |
| WO2022139537A9 (ko) | 2022-11-17 |
| WO2022139537A2 (ko) | 2022-06-30 |
| WO2022139537A4 (ko) | 2022-10-06 |
| CA3203067A1 (en) | 2022-06-30 |
| TW202233667A (zh) | 2022-09-01 |
| IL303902A (en) | 2023-08-01 |
| CO2023009764A2 (es) | 2023-09-08 |
| WO2022139537A3 (ko) | 2022-09-09 |
| CL2023001873A1 (es) | 2024-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126242A2 (es) | Tratamiento del cáncer utilizando receptores de antígenos quiméricos | |
| JP2019525771A5 (es) | ||
| PE20220495A1 (es) | Receptores antigenicos quimericos y agentes de union dirigidos a dll3 | |
| KR102392598B1 (ko) | 삼관능성 항원-결합 분자 | |
| AR127371A2 (es) | Receptores quiméricos de flt3 y métodos para usarlos | |
| HRP20220799T1 (hr) | Klaudin-18-2-specifični imunoreceptori i stanični epitopi t | |
| PE20200400A1 (es) | Receptores quimericos y metodos de uso de los mismos | |
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| AR110979A1 (es) | Moléculas de unión a cd70 y métodos de uso de las mismas | |
| IL268620B2 (en) | Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment | |
| US20210024630A1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| CU20190099A7 (es) | Dominio de unión a antígeno anti-trbc1, y receptor de antígeno quimérico, anticuerpo, acoplador biespecífico de células t y conjugado anticuerpo-fármaco que comprenden el mismo | |
| JP2016508518A5 (es) | ||
| RU2018109426A (ru) | Химерные антигенные рецепторы со встроенными контролируемыми функциями | |
| PE20221909A1 (es) | Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf | |
| HRP20211978T1 (hr) | Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe | |
| AR097405A1 (es) | Diacuerpos monovalentes biespecíficos que son capaces de unirse a cd123 y cd3 y usos de los mismos | |
| PE20140178A1 (es) | Uso de celulas t modificadas con receptor de antigeno quimerico para tratar el cancer | |
| TW201904997A (zh) | 引導及導航控制蛋白質以及彼之製造及使用方法 | |
| AR078254A1 (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| RU2018135097A (ru) | Комбинация модулятора иммунных контрольных точек и комплекса, содержащего проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr, для применения в медицине | |
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| PE20121649A1 (es) | Anticuerpos monoclonales frente a progastrina y sus usos | |
| Stamova et al. | Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses | |
| PE20221273A1 (es) | Receptores del antigeno quimerico anti-cd79, celulas car-t, y usos de estos |